Helios, a member of the Ikaros transcription factor family, is preferentially expressed at the mRNA level by regulatory T cells (Treg cells). We evaluated Helios protein expression using a newly generated mAb and demonstrated that it is expressed in all thymocytes at the double negative 2 stage of thymic development. Although Helios was expressed by 100% of CD4 + CD8 2 Foxp3 + thymocytes, its expression in peripheral lymphoid tissues was restricted to a subpopulation (∼70%) of Foxp3 + T cells in mice and humans. Neither mouse nor human naive T cells induced to express Foxp3 in vitro by TCR stimulation in the presence of TGF-b expressed Helios. Ag-specific Foxp3 + T cells induced in vivo by Ag feeding also failed to express Helios. Collectively, these results demonstrate that Helios is potentially a specific marker of thymic-derived Treg cells and raises the possibility that a significant percentage of Foxp3 + Treg cells are generated extrathymically.
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R egulatory T cells (Treg cells) suppress immune activation
in a dominant manner and, thus, play a critical role in the maintenance of self-tolerance (1) (2) (3) . Treg cells are characterized by the expression of the transcription factor Foxp3; the importance of Treg cells in immune homeostasis is best illustrated by the development of severe autoimmune diseases in mice and humans with genetic deficiencies of Foxp3 (4, 5) . It is believed that there are two major subsets of Treg cells: natural, or thymic-derived Treg cells, which develop in the thymus and induced Treg cells, conventional Foxp3
2 T cells that are converted in peripheral lymphoid tissue to cells that express Foxp3. Although it was demonstrated that Treg cells can be generated in vitro and in vivo in the periphery, specifically in the gut, the lack of a specific marker or markers has precluded the demonstration that peripherally induced Treg cells exist under physiologic conditions (3) . The Ikaros transcription factor family is made up of five DNAbinding proteins that are characterized by six highly conserved C2H2 zinc fingers. Four N-terminal zinc fingers are involved in DNA binding, whereas the two C-terminal zinc fingers are responsible for homodimeric and heterodimeric protein interactions (6) . Two members, Eos and Pegasus, are expressed in a wide variety of tissues, whereas the remaining three, Ikaros, Helios, and Aiolos, are reportedly limited to the hematopoietic system. Ikaros is expressed in all hematopoietic cells, including very early hematopoietic stem cells, whereas Aiolos is expressed in most hematopoietic cells, although not in the earliest uncommitted cells (7) . Aiolos is observed in committed cells of the lymphoid lineage and is very highly expressed in mature B cells. However, Helios seems to be restricted to the T lymphocyte lineage (8, 9) .
Targeted mutations of the Ikaros and Aiolos genes demonstrated the importance of this family in lymphocyte development and homeostasis. Mice with a null mutation of Ikaros lack B and NK cells and have greatly reduced numbers of thymic dendritic cells (10) . In addition, fetal T cells are absent; however, a small number of T cells do develop after birth but are skewed toward the CD4 subpopulation and are hyperproliferative. Mice that are homozygous for a dominant negative mutation of Ikaros also lack B and NK cells and are devoid of all T cells and early lymphoid progenitors (11) . The pups fail to thrive and die within 3 wk of cannibalism or opportunistic infections. Mice that are heterozygous for the same dominant negative mutation exhibit a less severe phenotype (12) . Although lymphocyte populations seem normal during the first 4 wk of life, T cells from heterozygous mice are hyperproliferative, and the mice develop leukemia and lymphoma. Finally, mice with a targeted mutation of Aiolos have elevated serum IgG and IgE and possess autoantibodies (13) . These mice have more germinal centers, their B cells display an activated phenotype, B cells are hyperproliferative in vitro, and by 8-10 mo the mice develop B cell lymphomas.
Despite the clear importance of the Ikaros family, their mechanisms of action are still poorly understood. Ikaros family members are thought to regulate gene transcription through chromatin remodeling, and studies showed that Ikaros and Helios interact in the nucleosome remodeling and the DNA methylation complex, an ATP-dependent complex that has nucleosome-disruption activity and histone deacetylase activity (14, 15) . Furthermore, Ikaros was shown to bind to the IL-2 promoter and repress expression, whereas reduced binding of Ikaros releases the requirement for CD28 costimulation for IL-2 expression (16).
Helios was originally cloned from a mouse thymoma line and was reportedly expressed by an undefined subpopulation of T cells (9 
Materials and Methods

Animals
BALB/c and C57BL/6 mice were obtained from the National Cancer Institute (Frederick, MD). Foxp3-GFP mice (21) fl/fl mice were bred in our laboratory to mice expressing Cre recombinase under the control of the CD4 promoter (CD4-Cre) to produce Ikzf2 fl/fl 3 CD4-Cre mice, which will be described elsewhere (A.M. Thornton, J. Murphy, and E.M. Shevach, manuscript in preparation). CD4-Cre mice were obtained from Taconic Farms. All animal protocols used in this study were approved by the NIAID Animal Care and Use Committee.
Human cells
Peripheral blood was obtained from healthy adult donors by the Department of Transfusion Medicine at the National Institutes of Health. The acquisition of blood products was approved according to the Institutional Review Board and in accordance with the Declaration of Helsinki.
Media, Abs, and reagents
Mouse cells were grown in RPMI 1640 (Lonza, Walkersville, MD) supplemented with 10% heat-inactivated FCS, penicillin (100 mg/ml), streptomycin (100 mg/ml), 2 mM L-glutamine, 10 mM HEPES, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate (all from Lonza), and 50 mM 2-ME (Sigma-Aldrich, St. Louis, MO). Purified anti-CD3 (2C11), PEanti-CD25 (PC61), and FITC-anti-CD8 were purchased from BD Biosciences (San Jose, CA). Mouse Abs included tricolor-anti-CD4 (Invitrogen, Carlsbad, CA) and Alexa Fluor 647 anti-Foxp3, PE anti-FoxP3, PE-Cy7 anti-CD8, Pacific Blue anti-CD4, Alexa Fluor 750 anti-CD45.1, PE-Cy5.5 anti-CD45.2, and Alexa Fluor 700 anti-CD44 (eBioscience, San Diego, CA). Human Abs included FITC anti-CD4, PE-Cy5.5 anti-CD45RA, PE anti-CD25, allophycocyanin anti-IL-2, and allophycocyanin anti-IFN-g (Invitrogen); Alexa Fluor 647 anti-CD127 and anti-CD28 (BD Biosciences); Alexa Fluor 647 anti-human FOXP3 (236A/E7) and Alexa Fluor 647 anti-IL-17 (eBioscience); and anti-CD3 (OKT3; Ortho Biotech Products, Bridgewater, NJ). CD8, CD4, and PE microbeads were purchased from Miltenyi Biotec (Auburn, CA). Intracellular staining was performed with the Foxp3 staining buffer kit, according to the manufacturer's protocol (eBioscience). Flow cytometry analysis was performed using FlowJo software. Human rIL-2 was obtained from the Preclinical Repository of the Biological Resources Branch, National Cancer Institute. TGF-b1 was purchased from PeproTech (Rocky Hill, NJ).
Cell purification, activation, and RNA isolation of mouse cells Peripheral lymph nodes (LNs) were harvested from 8-wk-old female BALB/c or C57BL/6 mice. CD4 + CD25
2 and CD4 + CD25 + cells were purified as previously described (22) . The purity of CD4 +
CD25
2 and CD4 + CD25
+ cells was ∼97%. CD8 + T cells were purified from mouse LNs using CD8 microbeads. For thymic subpopulations, cells were labeled with PE anti-CD25, tricolor anti-CD4, or FITC anti-CD8 and were purified by cell sorting. For cell activation, purified cells (10 6 /ml) were cultured in complete RPMI 1640 supplemented with 100 U/ml IL-2 at 37˚C for 16 h in 24-well plates precoated with 5 mg/ml anti-CD3. RNA was purified using TRIzol reagent (Invitrogen), according to manufacturer's instructions.
PCR-based cDNA subtraction
Total RNA was subjected to PCR-Select cDNA Subtraction, followed by mirror-orientation selection (BD Clontech, Palo Alto, CA) (23) . The CD4 +
CD25
+ T cell-specific library resulted in 106 clones. cDNA inserts were sequenced by Lofstrand Labs (Gaithersburg, MD).
Quantitative PCR
RNA from purified or purified and activated cells was isolated using an RNeasy Plus kit (Qiagen, Valencia, CA). RNA was converted to cDNA using SuperScript II reverse transcriptase (Invitrogen) with random primers, according to the manufacturer's protocol. Primers and FAM-labeled probes were purchased from Integrated DNA Technologies (San Diego, CA). Helios forward: 59-TCACAACTATCTCCAGAATGTCAGC-39; reverse: 59-AGGCGGTACATGGTGACTCAT-39; probe: 59-TGGAGGCTGCCG-GGCAGG-39. Foxp3 forward: 59-CCCAGGAAAGACAGCAACC-39TT; reverse: 59-TTCTCACAACCAGGCCACTTG-39; probe: 59-ATCCTACC-CACTGCTGGCAAATGGAGTC-39. 18S rRNA (Applied Biosystems, Foster City, CA) was used as an internal control for normalization. All PCR reactions were performed in triplicate using TaqMan Universal PCR Master Mix (Applied Biosystems). An ABI prism 7700 sequence detection system (Applied Biosystems) was used for 40 cycles of PCR. Each experiment was performed at least three times, and a representative experiment is shown.
Generation of the 22F6 anti-Helios mAb
A peptide from the Helios protein (aa 51-107) was synthesized by the NIAID Peptide Synthesis Laboratory (Bethesda, MD) and was used to immunize Armenian hamsters. Spleens from immunized animals were fused with SP2/0-Ag14 mouse myeloma cells. Hybridoma supernatants were first screened by ELISA using the peptide and HRP conjugated goat anti-Armenian Hamster IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). Supernatants were screened by Western blot analysis on EL-4 whole-cell extracts using HRP-conjugated goat anti-Armenian Hamster IgG or by flow cytometry using intracellular staining methods and FITC-conjugated goat anti-Armenian Hamster IgG as the secondary Ab. The mAb 22F6 was subsequently conjugated to FITC or PE by the NIAID Custom Ab Facility (Bethesda, MD) or to FITC, PE, or Alexa Fluor 647 by BioLegend (San Diego, CA).
Cell purification and activation of human cells
PBMCs were prepared over Ficoll-Paque Plus gradients (GE Healthcare, Piscataway, NJ). The CD4 + T cells were enriched by autoMACS positive selection with human CD4 microbeads. The cells were labeled with anti-CD4, anti-CD45RA, anti-CD25, and anti-CD127 and purified by cell sorting with BD Aria. The postsort purity was .95% for CD4 + CD25 hi cells. The cells were activated in vitro with plate-bound anti-CD3 (5 mg/ml) and soluble anti-CD28 (2.5 mg/ml), with or without 5 ng/ml TGF-b1 in 24-well culture plates (Corning Life Sciences, Acton, MA) at 500,000 cells per well in complete RPMI 1640 supplemented with 100 U/ml IL-2.
Proliferation and suppression assay
Purified cells were cultured as previously described (22) . For human in vitro suppression assays, 50,000 FACS-sorted allogenic CD4 
Generation of mouse-induced Treg cells
CD4
+ GFP 2 cells and CD4 + GFP + cells from the LN and spleen of Foxp3-GFP reporter mice were purified by cell sorting. For cell activation, purified cells (10 6 /ml) were cultured in complete RPMI 1640 supplemented with 100 U/ml IL-2 at 37˚C for 3 d in 24-well plates precoated with 5 mg/ ml anti-CD3 in the presence or absence of 5 ng/ml TGF-b.
Oral tolerance induction
neg T cells from OT-II TCR Tg 3 Foxp3-GFP mice were purified from the spleen and LN by cell sorting. Two million cells were transferred i.v. into B6.SJL congenic mice. The mice were given 1.5% OVA-supplemented water for 6 d; the water was changed every 2 d.
Thymocyte transfer
2 GFP + thymocytes were purified from the thymus of 4-wk-old Foxp3-GFP mice. A total of 6 3 10 5 cells were transferred i.v. Cells were harvested 4 wk later and analyzed by flow cytometry.
Results
Helios is differentially expressed in Treg cells
To elucidate genes specific to CD4 + CD25 + Treg cells, RNA isolated from CD4 + CD25 2 and CD4 + CD25 + cells was subjected to Clontech PCR Select Differential Screening, followed by mirror-oriented selection (23) . Of the 106 clones specific to the CD4 + CD25 + Treg cell library, 54 clones contained a fragment of the Helios gene (Supplemental Table I ). Helios expression was analyzed by quantitative PCR (qPCR) to validate the differential screening (Supplemental Fig. 1A ). Helios mRNA was detected in freshly isolated CD4 + CD25 + cells, and it increased ∼3-fold upon activation of the cells. Helios was not detected in freshly isolated or activated CD4 + CD25
2 cells, and it was barely detectable in CD8 + cells. We were unable to detect mRNA for Helios in B cells, dendritic cells, or cells of the monocyte/macrophage lineage (data not shown). To further characterize Helios, we examined Helios mRNA expression in various thymic subpopulations. We observed that Helios was expressed in the thymus at low levels as early as the double negative (DN) stage (Supplemental Fig. 1B ). Helios continued to be expressed at low levels in double positive (DP) cells, CD8
+ cells, and CD4 + CD25 2 cells. However, there was a striking increase in Helios mRNA in thymic CD4 + CD25 + cells, concurrent with the first appearance of Foxp3 mRNA (Supplemental Fig. 1C) . In peripheral LNs, Helios expression correlated with Foxp3 expression and was detected exclusively in Treg cells.
Development of an anti-mouse/human Helios mAb
All members of the Ikaros family of transcription factors contain a large region of six highly conserved zinc fingers. However, the N terminus of the members is not conserved. To more thoroughly examine Helios expression and function, we generated a mAb (22F6) to a large peptide within the nonconserved 110-aa N terminus region of Helios. When Helios expression was analyzed by intracellular staining of permeabilized cells with this mAb, 10% of CD4 + T cells in the peripheral LN of mice were positive (Fig. 1A) + cells in man, which is strikingly similar to that observed in mice (Fig. 1C) .
Expression of Helios during T cell development
Because our qPCR studies suggested that Helios mRNA was expressed at different stages of thymic development, we used mAb 22F6 to examine the expression of Helios protein in subsets of adult mouse thymocytes. Helios was expressed at the DN stage of development, in agreement with the qPCR data ( Fig. 2A) . Specifically, Helios was expressed at low levels as early as DN1, but it was expressed in 100% of DN2 and DN3 cells. By DN4, Helios expression had begun to decrease. In contrast, Foxp3 was not expressed at the DN stage. Although Foxp3 + Helios 2 T cells could be detected in the adult thymus ( Fig. 2A ), they were absent at day 3 of life, when Foxp3 + cells first appear in the thymus (Fig. 2B) (Fig. 3A) . Phenotypic analysis of the Foxp3 + Helios + cells shows that the vast majority of the cells in the thymus (Fig. 2B ) and peripheral lymphoid tissue (Fig. 3B) are (Fig. 4) 
Helios
2 T cells are primarily generated from conventional T cells in the periphery, one might predict that these cells are intrinsically more prone to exhibit plasticity. In particular, a subpopulation of human FOXP3 + cells was recently shown to produce IL-17 when stimulated in the presence of proinflammatory cytokines. Therefore, it was of interest to examine the cytokine-expression profile of human FOXP3
+ cells based on Helios expression. When human PBMCs were stimulated with PMA and ionomycin for 5 h and cytokine production by Foxp3 + T cells was analyzed by intracellular staining, low, but significant, numbers of IL-2-and -17-and IFN-g-producing cells were detected; however, these were present almost exclusively within the Foxp3 + Helios 2 population (Fig. 6) . Thus, the lack of expression of Helios seems to define a Treg cell population with the potential for plasticity.
Expression of Helios is not required for Treg cell function
Because Helios expression in the thymus precedes Foxp3, we examined the possibility that Helios could regulate the expression of Foxp3. We generated Ikzf2 fl/fl mice (Supplemental Fig. 2 ) and crossed them to CD4-Cre mice (Ikzf2 fl/fl 3 CD4-Cre). Because Helios is expressed prior to CD4 in the thymus, Helios expression is only slightly reduced in DN thymocytes, but it is virtually absent by the CD4 single-positive stage (Supplemental Fig. 3 ). However, despite the deletion of Helios in peripheral CD4 + T cells, Foxp3 expression remains unchanged (Fig. 7A) . Thus, Helios does not seem to regulate Foxp3 expression, nor does Foxp3 seem to be required for Helios expression. Because Foxp3 was reported to bind to the Helios promoter, and thus, possibly regulate its expression, we examined the expression of Helios in Scurfy mice that possess a mutation in the Foxp3 gene that results in the absence of Foxp3 protein. Because these mice die at an early age, they were examined at 4 or 17 d after birth. Despite the absence of Foxp3, Helios was expressed in the thymus and spleen of Scurfy mice (Supplemental Fig. 4) .
To examine the function of Helios in Treg cells, we purified CD4 + CD25 + T cells from Ikzf2 fl/fl 3 CD4-Cre mice and assayed the cells for suppressive function in vitro. Treg cells deficient for Helios were nonresponsive to TCR stimulation and failed to respond to IL-2, but they responded to anti-CD3 and IL-2 in a manner similar to Treg cells from WT mice (Fig. 7B) . In addition, Treg cells from the Helios 2/2 mice were as suppressive as Treg cells from WT mice (Fig. 7C) . Helios expression in expanded human CD4 + CD127
2
CD25
hi Treg cells was markedly reduced following electroporation of Helios small interfering (siRNA). The loss of Helios expression http://www.jimmunol.org/ did not reverse the nonresponsiveness of the Treg cells nor did it impair their suppressive capacity (Fig. 7D) .
Discussion
We initially used PCR-based cDNA subtraction followed by qPCR to determine that the transcription factor Helios is preferentially expressed in Treg cells. Treg cell-specific expression of Helios was also found using microarray analyses (18, 19) , and, very recently, a study by Cai et al. (31) confirmed these findings by Western blot analysis. We now extend these findings and demonstrate, by intracellular staining using a mAb to a 55-aa fragment from the nonconserved N-terminal region of Helios, that Helios is expressed in mouse and human Foxp3 + Treg cells in peripheral sites but that its expression is limited to only 70% of Foxp3 + Treg cells in either species. In addition, Helios is expressed at the DN2 stage of thymic development in the mouse, prior to Foxp3 expression.
Because the expression of Helios clearly divides the peripheral pool of Foxp3 + T cells into two defined populations, we attempted to determine whether these two populations were derived from distinct progenitors or whether they manifested distinct functions. We are unable to isolate the Foxp3 + Helios 2 population, so our approach has been indirect and correlative. It seems that the Foxp3 + Helios 2 population is generated in the periphery, because We first noted that Foxp3 + T cells in MHC class II 2/2 mice were uniformly Helios + . The majority of Foxp3 + T cells in these mice is CD8 + and is likely to be thymic derived (25 (36, 37) . (39) reported the repertoire similarities to be 25%, whereas Pacholczyk et al. (40) reported the similarity to be between 10% and 20%, and Wong et al. (41) found a 42% similarity. One interpretation of these studies is that the overlap between the TCR repertoires represents induced Foxp3 + Treg cells, because they would presumably express the same TCR repertoire as conventional T cells. Intriguingly, Pacholczyk et al. (40) also reported that the overlap between the TCR repertoires of thymic Treg cells and peripheral LN Treg cells was 65%. If one assumes that the Treg cells isolated from thymus are primarily generated in the thymus, whereas the peripheral LN Treg cells would contain a mixture of thymic-derived and peripherally induced Treg cells, the 65% overlap in repertoires is strikingly close to the percentage (70%) of Foxp3 + Helios + T cells that we detect in peripheral sites.
Our data suggest that peripheral conversion accounts for 30% of all Treg cells. This is in stark contrast to a recent study in which extrapolated data determined that peripheral conversion accounted for 4-7% of CD4 + Foxp3 + cells (42) . However, Lathrop et al. (42) also emphasized that the estimate of ∼4-7% conversion was based on a steady-state study that may "underestimate the role of peripheral conversion." Indeed, a higher rate of conversion was observed after adoptive transfer into lymphopenic hosts. Our studies show that the + T cells are heterogeneous and are composed of a major subset that is committed to the Treg cell lineage, whereas a minor subset (∼8%) possesses a "plastic" phenotype and can lose Foxp3 expression. This result is consistent with our observation that a highly enriched population of Foxp3 + Helios + T cells isolated from neonatal thymocytes retains expression of Foxp3 and Helios following transfer to normal recipients. Similarly, our data demonstrating that effector cytokine production is restricted to the human FOXP3 + Helios 2 population is consistent with the possibility that the less committed or "plastic" Treg cells are exclusively found in the Foxp3 + Helios 2 pool.
Lastly, there is a great deal of interest in the analysis of Treg cell function in disease and in the therapeutic use of Treg cells (46) . Our results suggest that a significant component of the Foxp3 + T cells population is likely to be composed of induced Treg cells and that this subpopulation is likely to be quite distinct from thymic-derived Treg cells in terms of TCR repertoire expression, stability, and potentially many other characteristics. Furthermore, it is unclear whether defects in Treg cell function will be confined to one or the other of these subpopulations or which subpopulation would be most suited for in vitro expansion and cellular biotherapy. A detailed comparison of the Foxp3 + Helios + and Foxp3 + Helios 2 subpopulations will require generation of a reporter mouse and identification of a cell-surface Ag that will distinguish the subpopulations in humans.
